{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T05:36:36Z","timestamp":1783488996489,"version":"3.55.0"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.bone.2024.117219","type":"journal-article","created":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T02:44:32Z","timestamp":1722393872000},"page":"117219","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Efficacy and safety of asfotase alfa in patients with hypophosphatasia: A systematic review"],"prefix":"10.1016","volume":"188","author":[{"given":"Amirhossein","family":"Shirinezhad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5335-3235","authenticated-orcid":false,"given":"Sina","family":"Esmaeili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3399-2360","authenticated-orcid":false,"given":"Alireza","family":"Azarboo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0542-9490","authenticated-orcid":false,"given":"Yasaman","family":"Tavakoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4607-354X","authenticated-orcid":false,"given":"Amir Human","family":"Hoveidaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Negar","family":"Zareshahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4322-0236","authenticated-orcid":false,"given":"Amirhossein","family":"Ghaseminejad-Raeini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.bone.2024.117219_bb0005","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/nrendo.2016.14","article-title":"Hypophosphatasia - aetiology, nosology, pathogenesis, diagnosis and treatment","volume":"12","author":"Whyte","year":"2016","journal-title":"Nat. Rev. Endocrinol."},{"issue":"2","key":"10.1016\/j.bone.2024.117219_bb0010","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S2213-8587(18)30307-3","article-title":"Asfotase alfa for infants and young children with hypophosphatasia: 7 year outcomes of a single-arm, open-label, phase 2 extension trial","volume":"7","author":"Whyte","year":"2019","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.bone.2024.117219_bb0015","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.bone.2017.02.011","article-title":"Hypophosphatasia: an overview for 2017","volume":"102","author":"Whyte","year":"2017","journal-title":"Bone"},{"key":"10.1016\/j.bone.2024.117219_bb0020","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.bone.2014.11.017","article-title":"Improvement of the skeletal and dental hypophosphatasia phenotype in Alpl-\/- mice by administration of soluble (non-targeted) chimeric alkaline phosphatase","volume":"72","author":"Gasque","year":"2015","journal-title":"Bone"},{"key":"10.1016\/j.bone.2024.117219_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2021.116089","article-title":"Dental outcomes for children receiving asfotase alfa for hypophosphatasia","volume":"152","author":"Schroth","year":"2021","journal-title":"Bone"},{"key":"10.1016\/j.bone.2024.117219_bb0030","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.bone.2015.02.022","article-title":"Hypophosphatasia: validation and expansion of the clinical nosology for children from 25 years experience with 173 pediatric patients","volume":"75","author":"Whyte","year":"2015","journal-title":"Bone"},{"issue":"2","key":"10.1016\/j.bone.2024.117219_bb0035","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0917-2394(12)70266-5","article-title":"Oral manifestations of patients with hypophosphatasia","volume":"22","author":"Okawa","year":"2012","journal-title":"Pediatr. Dent. J."},{"issue":"12","key":"10.1016\/j.bone.2024.117219_bb0040","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1007\/s00198-015-3272-1","article-title":"Hypophosphatasia: an overview of the disease and its treatment","volume":"26","author":"Bianchi","year":"2015","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2024.117219_bb0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2023.116947","article-title":"The global ALPL gene variant classification project: Dedicated to deciphering variants","volume":"178","author":"Farman","year":"2024","journal-title":"Bone"},{"key":"10.1016\/j.bone.2024.117219_bb0050","first-page":"73","article-title":"Outcome of perinatal hypophosphatasia in Manitoba mennonites: a retrospective cohort analysis","volume":"11","author":"Leung","year":"2013","journal-title":"JIMD Rep."},{"issue":"1","key":"10.1016\/j.bone.2024.117219_bb0055","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1210\/jc.2015-3462","article-title":"Asfotase alfa treatment improves survival for perinatal and infantile hypophosphatasia","volume":"101","author":"Whyte","year":"2016","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"5","key":"10.1016\/j.bone.2024.117219_bb0060","doi-asserted-by":"crossref","DOI":"10.1530\/EC-22-0240","article-title":"Growth and disease burden in children with hypophosphatasia","volume":"12","author":"H\u00f6gler","year":"2023","journal-title":"Endocr. Connect."},{"issue":"9","key":"10.1016\/j.bone.2024.117219_bb0065","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22094303","article-title":"Hypophosphatasia: a unique disorder of bone mineralization","volume":"22","author":"Villa-Su\u00e1rez","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"7","key":"10.1016\/j.bone.2024.117219_bb0070","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1210\/jc.2018-02335","article-title":"Efficacy and safety of asfotase alfa in infants and young children with hypophosphatasia: a phase 2 open-label study","volume":"104","author":"Hofmann","year":"2019","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2024.117219_bb0075","author":"E.M. Agency"},{"issue":"9","key":"10.1016\/j.bone.2024.117219_bb0080","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.85971","article-title":"Asfotase alfa therapy for children with hypophosphatasia","volume":"1","author":"Whyte","year":"2016","journal-title":"JCI Insight"},{"issue":"7","key":"10.1016\/j.bone.2024.117219_bb0085","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med."},{"issue":"1","key":"10.1016\/j.bone.2024.117219_bb0090","first-page":"7","article-title":"Methodological quality (risk of bias) assessment tools for primary and secondary medical studies: what are they and which is better?","volume":"7","author":"Ma","year":"2020","journal-title":"Mil. Med. Res."},{"issue":"6","key":"10.1016\/j.bone.2024.117219_bb0095","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1097\/01.NAJ.0000450430.97383.64","article-title":"JBI\u2019s systematic reviews: study selection and critical appraisal","volume":"114","author":"Porritt","year":"2014","journal-title":"Am. J. Nurs."},{"issue":"4","key":"10.1016\/j.bone.2024.117219_bb0100","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1007\/s00198-023-06943-z","article-title":"Hypophosphatasia: presentation and response to asfotase alfa","volume":"35","author":"Alsarraf","year":"2024","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2024.117219_bb0105","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.bone.2018.12.011","article-title":"Five-year efficacy and safety of asfotase alfa therapy for adults and adolescents with hypophosphatasia","volume":"121","author":"Kishnani","year":"2019","journal-title":"Bone"},{"issue":"1","key":"10.1016\/j.bone.2024.117219_bb0110","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/cen.13343","article-title":"Safety and efficacy of treatment with asfotase alfa in patients with hypophosphatasia: results from a Japanese clinical trial","volume":"87","author":"Kitaoka","year":"2017","journal-title":"Clin. Endocrinol. (Oxf)"},{"issue":"1","key":"10.1016\/j.bone.2024.117219_bb0115","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1186\/s13023-020-01483-9","article-title":"Characterization of tracheobronchomalacia in infants with hypophosphatasia","volume":"15","author":"Padidela","year":"2020","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.bone.2024.117219_bb0120","article-title":"Impact of discontinuing 5 years of enzyme replacement treatment in a cohort of 6 adults with hypophosphatasia: a case series","volume":"17","author":"Rockman-Greenberg","year":"2022","journal-title":"Bone Rep."},{"key":"10.1016\/j.bone.2024.117219_bb0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2023.116856","article-title":"Effects of asfotase alfa in adults with pediatric-onset hypophosphatasia over 24 months of treatment","volume":"175","author":"Seefried","year":"2023","journal-title":"Bone"},{"key":"10.1016\/j.bone.2024.117219_bb0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2020.115664","article-title":"Pharmacodynamics of asfotase alfa in adults with pediatric-onset hypophosphatasia","volume":"142","author":"Seefried","year":"2021","journal-title":"Bone"},{"issue":"12","key":"10.1016\/j.bone.2024.117219_bb0135","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1007\/s00198-021-06025-y","article-title":"Bone turnover and mineral metabolism in adult patients with hypophosphatasia treated with asfotase alfa","volume":"32","author":"Seefried","year":"2021","journal-title":"Osteoporos. Int."},{"issue":"1","key":"10.1016\/j.bone.2024.117219_bb0140","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s13023-022-02230-y","article-title":"A Japanese single-center experience of the efficacy and safety of asfotase alfa in pediatric-onset hypophosphatasia","volume":"17","author":"Sugiyama","year":"2022","journal-title":"Orphanet J. Rare Dis."},{"issue":"1","key":"10.1016\/j.bone.2024.117219_bb0145","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s13023-024-03048-6","article-title":"Effectiveness of asfotase alfa for treatment of adults with hypophosphatasia: results from a global registry","volume":"19","author":"Kishnani","year":"2024","journal-title":"Orphanet J. Rare Dis."},{"issue":"Suppl. 1","key":"10.1016\/j.bone.2024.117219_bb0150","article-title":"Effect of asfotase alfa in the treatment of hypophosphatasia- a systematic review","volume":"15","author":"Jaswanthi","year":"2023","journal-title":"J. Pharm. Bioallied Sci."},{"issue":"4","key":"10.1016\/j.bone.2024.117219_bb0155","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s40368-023-00796-0","article-title":"The impact of enzyme replacement therapy on the oral health manifestations of hypophosphatasia among children: a scoping review","volume":"24","author":"Smart","year":"2023","journal-title":"Eur. Arch. Paediatr. Dent."},{"key":"10.1016\/j.bone.2024.117219_bb0160","doi-asserted-by":"crossref","first-page":"3147","DOI":"10.2147\/DDDT.S154922","article-title":"Profile of asfotase alfa in the treatment of hypophosphatasia: design, development, and place in therapy","volume":"12","author":"Bowden","year":"2018","journal-title":"Drug Des. Devel. Ther."},{"issue":"16","key":"10.1016\/j.bone.2024.117219_bb0165","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22168947","article-title":"The role of fc receptors on the effectiveness of therapeutic monoclonal antibodies","volume":"22","author":"Gogesch","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.bone.2024.117219_bb0170","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s13238-017-0473-8","article-title":"IgG fc engineering to modulate antibody effector functions","volume":"9","author":"Wang","year":"2018","journal-title":"Protein Cell"},{"issue":"12","key":"10.1016\/j.bone.2024.117219_bb0175","doi-asserted-by":"crossref","DOI":"10.1002\/jbm4.10842","article-title":"The effect of asfotase alfa on plasma and urine pyrophosphate levels and pseudofractures in a patient with adult-onset hypophosphatasia","volume":"7","author":"Hidaka","year":"2023","journal-title":"JBMR Plus"},{"issue":"5","key":"10.1016\/j.bone.2024.117219_bb0180","doi-asserted-by":"crossref","DOI":"10.20945\/2359-3997000000626","article-title":"Hypophosphatasia: from birth to adulthood","volume":"67","author":"Reis","year":"2023","journal-title":"Arch. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2024.117219_bb0185","author":"O.O.C.A.f.D.a.T.i. Health"},{"key":"10.1016\/j.bone.2024.117219_bb0190","author":"O.O.C.A.f.D.a.T.i. Health"},{"issue":"1","key":"10.1016\/j.bone.2024.117219_bb0195","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1186\/s13023-018-0869-4","article-title":"Healthcare resource utilization in the management of hypophosphatasia in three patients displaying a spectrum of manifestations","volume":"13","author":"Daniel","year":"2018","journal-title":"Orphanet J. Rare Dis."}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328224002084?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328224002084?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T17:51:36Z","timestamp":1736531496000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S8756328224002084"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":39,"alternative-id":["S8756328224002084"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2024.117219","relation":{},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of asfotase alfa in patients with hypophosphatasia: A systematic review","name":"articletitle","label":"Article Title"},{"value":"Bone","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bone.2024.117219","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117219"}}